Skip to main content
BBNX logo

Beta Bionics, Inc. (BBNX) Stock: Price, Forecast & Analyst Target

Beta Bionics, Inc. (BBNX) — MoonshotScore 30/100 (Weak band), calculated Nov 22, 2026. Price $13.36 (+0.30%), as of the Nov 20, 2026 trading session; market cap $601M.

Educational signal · not a buy or sell recommendation · How to read this

$13.36 +$0.04 (+0.30%) Market Cap $601M

Beta Bionics, Inc. · BBNX · NASDAQ

Beta Bionics, Inc. is a commercial-stage medical device company focused on developing and commercializing solutions for people with diabetes.

Price as of Nov 20, 2026

Key Statistics

30 of 100

MoonshotScore v2 · Beta Bionics (BBNX)

Weak
Business Quality Thin (26)
Financial Safety Okay (54)
Valuation Full (56)
Growth Durability Flat (54)
Momentum Quiet (49)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Weak quality and a full valuation, though the balance sheet and growth are only middling. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Okay; Valuation: Full; Growth Durability: Flat; Momentum: Quiet.

  • EPS beat 0 of the last 4 reports
  • Altman Z 7.46 · Piotroski F 3
  • ROE -23.9% · ROA -15.0% · current ratio 8.92

Holding back: weak fundamentals

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for BBNX (58 recorded, newest six shown)
RecordedScoreBand
30Weak
30Weak
30Weak
30Weak
30Weak
30Weak

The score was 30 in the stored Nov 21, 2026 snapshot and remains 30 in the current publication computed Nov 22, 2026 (0); the largest pillar moves were Momentum -10 and Financial Safety -1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$13.36
Change on the day+0.30%
52-week range$8.80 – $32.71
Market capitalisation$601M
Shares traded on the day960.3K

Price & events

Other perspectives

Council score for Beta Bionics (BBNX): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Weak
Financial Safety Neutral
Valuation Neutral
Growth Durability Neutral
Momentum Neutral

Legends Council

2 lenses, 2 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 22, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Neutral
Margin of Safety Undervalued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Strong
ROE Negative
Gross Margin Moderate

Read on: Nov 20, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company more favourably than the MoonshotScore does: Munger lens (margin of safety). Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as undervalued against its own estimate of value.

Readings on this page are from Nov 22, 2026, except a card that shows its own read date.

1 · What is it?

What is Beta Bionics (BBNX), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Beta Bionics, Inc. (BBNX) is listed on NASDAQ. It employs 422 people and is led by Sean T. Saint. The market values it at $601M.

2 · Latest results

What do the latest results show for Beta Bionics (BBNX)?

Short answer · as of

Against analyst estimates the company has EPS beat 0 of the last 4 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$27M-$14M-$0.33 (diluted)
Q4 FY2025$32M-$13M-$0.30 (diluted)
Q1 FY2026$28M-$22M-$0.49 (diluted)
Q2 FY2026$32M-$23M-$0.53 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Beta Bionics (BBNX)?

Short answer · as of

What is holding it back is weak fundamentals. The distress and quality screens read Altman Z 7.46 · Piotroski F 3. Trailing ratios: ROE -23.9% · ROA -15.0% · current ratio 8.92.

Data-derived red flags

  • Negative return on equity (-23.9%) — the business is not currently generating profit on shareholder capital.
  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at Beta Bionics (BBNX)?

Short answer · as of

Current published price targets run low $16.00 · high $30.00 · consensus $24.09 · median $24.00 against a quoted price of $13.36 (as of Nov 20, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Beta Bionics compare with its peers?

Short answer

Beta Bionics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Delcath Systems, Inc. (DCTH) Same industry, near in market value$18.79 Nov 20, 2026$654M94 5-pillar Nov 22, 2026
IRadimed Corporation (IRMD) Same industry, near in market value$81.02 Nov 20, 2026$1.04B94 5-pillar Nov 22, 2026
InMode Ltd. (INMD) Same industry, near in market value$12.42 Nov 20, 2026$715M93 5-pillar Nov 22, 2026
Tactile Systems Technology, Inc. (TCMD) Same industry, near in market value$25.60 Nov 20, 2026$573M90 5-pillar Nov 22, 2026
Bioventus Inc. (BVS) Same industry, near in market value$9.88 Nov 20, 2026$677M80 5-pillar Nov 22, 2026
Integra LifeSciences Holdings Corporation (IART) Same industry, near in market value$13.25 Nov 20, 2026$1.03B68 5-pillar Nov 22, 2026
Varex Imaging Corporation (VREX) Same industry, near in market value$18.10 Nov 20, 2026$769M63 5-pillar Nov 22, 2026
SI-BONE, Inc. (SIBN) Same industry, near in market value$23.73 Nov 20, 2026$1.07B40 5-pillar Nov 22, 2026
OrthoPediatrics Corp. (KIDS) Same industry, near in market value$31.74 Nov 20, 2026$829M37 5-pillar Nov 22, 2026
908 Devices Inc. (MASS) Same industry, near in market value$8.67 Nov 20, 2026$361M35 5-pillar Nov 22, 2026
Sight Sciences, Inc. (SGHT) Same industry, near in market value$10.18 Nov 20, 2026$566M34 5-pillar Nov 22, 2026
Artivion Inc. (AORT) Same industry, near in market value$18.16 Nov 20, 2026$886M34 5-pillar Nov 22, 2026
Beta Bionics (BBNX) — this page$13.36$601M30

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$16.00 – $30.00
Consensus target
$24.09
Median target
$24.00

Consensus record · Captured .

Measured against a quoted price of $13.36 (as of Nov 20, 2026).

Insider activity

Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Nov 11, 2026

Transactions
47
Identified insiders
6
Purchases
0
Sales
33
Other transactions
14

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held BBNX in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported BBNX in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Beta Bionics (BBNX)?

Read these with our analysis →

Investor Questions: BBNX Stock

These answers are editorial: 1 of these 9 answers is drawn from the BBNX research dossier (written May 9, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for BBNX?

BBNX carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is BBNX a good stock to buy?

Stock Expert AI does not rate BBNX buy, sell or hold. Beta Bionics, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the BBNX stock price today?

The last price recorded for Beta Bionics, Inc. (BBNX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the BBNX price target?

The analyst consensus price target for Beta Bionics, Inc. (BBNX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

How does Beta Bionics, Inc. navigate regulatory approval processes?

Beta Bionics, Inc. navigates regulatory approval processes, primarily with the FDA, by conducting rigorous clinical trials to demonstrate the safety and efficacy of its medical devices, such as the iLet Bionic Pancreas.

What are the key factors to evaluate for BBNX?

Beta Bionics, Inc. (BBNX) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. No Dividend Yield indicates that the company is reinvesting earnings for future growth. Not financial advice.

How frequently does BBNX data refresh on this page?

BBNX's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven BBNX's recent stock price performance?

Beta Bionics, Inc. (BBNX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative iLet Bionic Pancreas technology. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider BBNX overvalued or undervalued right now?

Beta Bionics, Inc. (BBNX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 18 figures on this page — 12 from Financial Modeling Prep (FMP), 4 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.